查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
病毒載體和質粒 DNA 製造市場 - 增長、未來展望、競爭分析，2023-2031 年
市場調查報告書
商品編碼
1293832

病毒載體和質粒 DNA 製造市場 - 增長、未來展望、競爭分析，2023-2031 年

Viral Vectors and Plasmid DNA Manufacturing Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

由於對先進基因療法、疫苗和細胞療法的需求不斷增加，預計 2023 年至 2031 年期間，病毒載體和質粒 DNA 製造市場將以 22.5% 的複合年增長率增長。Masu。 預計未來幾年市場收入將以可觀的複合年增長率（CAGR）顯著增長。 病毒載體和質粒 DNA 是基因治療和疫苗開發和生產的重要組成部分。 病毒載體，如腺病毒、慢病毒和腺相關病毒（AAV），用於將遺傳物質引入靶細胞，並可以改變或修改與各種疾病相關的特定基因。 另一方面，質粒 DNA 作為攜帶治療基因的載體，並為細胞內蛋白質合成提供必要的指令。 隨著生物技術和基因工程的進步，病毒載體/質粒 DNA 製造市場正在徹底改變醫學領域。 基因治療藥物在治療各種遺傳性疾病、罕見疾病和某些類型的癌症方面顯示出巨大的潛力。 此外，針對傳染病和癌症免疫療法的疫苗的開發進一步推動了對病毒載體和質粒DNA生產的需求。 COVID-19 大流行導致疫苗和治療方法的研發活動激增，進一步推動了該市場的增長。 多家製藥公司和研究機構致力於利用病毒載體和質粒 DNA 開發 COVID-19 疫苗和療法。 這場前所未有的全球健康危機凸顯了病毒載體和質粒 DNA 製造能力對於應對新出現的傳染病和公共衛生挑戰的重要性。

基因治療需求不斷增長

病毒載體和質粒 DNA 製造市場是由基因治療需求不斷增長所推動的。 基因治療是一種通過將功能基因引入患者細胞來治療多種遺傳性疾病的有前途的方法。 肌營養不良症、囊性纖維化和血友病等遺傳性疾病的患病率日益增加，推動了對基因治療的需求。 根據《美國醫學會雜誌》（JAMA）發表的一項研究，基因治療在多種遺傳性疾病的臨床試驗中顯示出顯著的治療效果。 針對以前無法治療的疾病和治療選擇有限的疾病的基因治療的成功，創造了對其生產中使用的病毒載體和質粒 DNA 的強勁市場需求。

病毒載體技術的進展

病毒載體技術的進步在推動病毒載體和質粒 DNA 製造市場的增長方面發揮著關鍵作用。 研究人員和生物製藥公司不斷致力於提高基因治療和疫苗中使用的病毒載體的效率、安全性和特異性。 例如，具有增強的基因轉移能力和降低的免疫原性的新一代腺相關病毒（AAV）的開發促成了多項基因治療試驗的成功。 發表在《分子治療》雜誌上的一項研究也證明了新型 AAV 變體實現有效基因轉移的潛力。 病毒載體技術的進步不僅提高了基因治療的功效，而且將其應用擴展到各個治療領域，進一步增加了對病毒載體/質粒DNA生產的需求。

增加生物技術研發投資

生物技術研發投資的增加推動了病毒載體和質粒 DNA 製造市場的發展。 各國政府、製藥公司和研究機構正在投入大量資金來開發基因療法和疫苗等創新療法。 例如，美國國立衛生研究院（NIH）在基因治療研究和支持臨床試驗方面投入了大量資金。 歐盟 (EU) 還通過其 Horizo□□n 2020 計劃投入大量資金，以推進生物技術和基因治療計劃。 這種對研發的投資促進了新技術的發現並導致先進療法的商業化。 不斷增加的財政支持以及對生物技術研究和開發的關注預計將在未來幾年推動病毒載體和質粒 DNA 製造市場的發展。

監管挑戰和安全擔憂

病毒載體和質粒 DNA 製造市場面臨監管挑戰和安全問題，這是市場增長的製約因素。 基因治療藥物和疫苗的開發和商業化需要嚴格的監管流程和安全評估，以確保產品的功效和安全性。 美國食品藥品監督管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構對病毒載體和質粒 DNA 的製造、質量控制和臨床測試制定了嚴格的指導方針和要求。 對於製造商來說，遵守這些法規既耗時又昂貴，並可能導致產品批准和市場准入的延遲。 此外，對與基因治療相關的潛在風險（例如免疫反應、脫靶效應和長期安全性）的擔憂也對這些療法的廣泛採用構成了挑戰。 臨床試驗中的不良事件和安全報告可能會影響人們對基因治療的認識和接受度，並影響對病毒載體和質粒 DNA 製造的需求。 例如，圍繞治療 X 連鎖嚴重聯合免疫缺陷病 (X-SCID) 的基因治療試驗的安全性問題導致試驗暫停。 這些監管挑戰和安全問題需要嚴格的監管合規和持續的研究，以確保基因療法和疫苗的安全性和有效性，這將成為DNA製造市場的製約因素。

從載體類型來看，腺病毒載體主導市場

病毒載體和質粒DNA製造市場可以按載體類型細分，包括腺病毒、逆轉錄病毒、腺相關病毒（AAV）、慢病毒和質粒。 其中，AAV 預計在 2023 年至 2031 年的預測期內復合年增長率最高。 AAV載體由於能夠有效地將治療基因遞送到具有低免疫原性和長期基因表達的靶細胞中，因此在基因治療應用中引起了相當大的關注。 AAV載體在Luxturna和Zolgensma等已批准的基因治療藥物中的使用證明了AAV載體在治療遺傳性疾病方面的潛力。 因此，對 AAV 載體的需求增加，推動了市場複合年增長率的增長。 在病毒載體和質粒DNA製造市場中，腺病毒載體將在2022年佔據銷售額的最高份額。 腺病毒載體因其高轉導效率和容納大DNA插入片段的能力而廣泛應用於基因治療研究和臨床試驗。 特別是，它在多種基因治療應用中取得了成功，例如癌症免疫治療和疫苗開發。 此外，穩健的腺病毒載體製造工藝和既定方案有助於腺病毒載體在市場上佔據主導收入地位。 包括慢病毒在內的逆轉錄病毒載體也佔據了很大的收入份額，這主要是由於它們在 CAR-T 細胞療法和基因工程細胞療法中的使用。 質粒作為基因克隆和重組DNA技術的重要工具，為市場帶來了收入，但增長率相對較低。 其他載體類型，例如單純皰疹病毒（HSV）載體和痘苗病毒載體，市場份額較小。 總之，腺病毒載體預計將產生最高的收入，而 AAV 載體由於其有前景的基因治療應用，預計將創下最高的複合年增長率。

北美地區引領收入，亞太地區引領增長

就收入而言，到 2022 年，北美將佔據病毒載體和質粒 DNA 製造市場的很大份額。 該地區擁有成熟的生物製藥產業、強大的研究基礎設施和有利的監管框架，促進基因療法和疫苗的開發和商業化。 此外，研發活動的投資不斷增加，尤其是在美國，這有助於市場收入的增長。 此外，歐洲是病毒載體/質粒DNA製造市場的重要地區，對盈利的貢獻很高。 主要生物製藥公司的存在、生物技術研究的進步以及政府的大力支持正在推動該地區的市場增長。 預計 2023 年至 2031 年預測期內，亞太地區的複合年增長率最高。 由於研發投資增加、醫療保健支出增加以及對個性化醫療的日益關注等因素，該地區生物技術領域呈現快速增長。 中國、日本和印度等國家利用其科學專業知識和擴大生物製藥能力，已成為病毒載體和質粒 DNA 製造市場的主要參與者。 拉美、中東/非洲等地區正在努力改善醫療基礎設施，引進先進醫療技術，市場穩步增長。

預測期內市場競爭將會加劇

病毒載體和質粒DNA製造市場競爭激烈，幾家大公司積極參與用於基因治療和疫苗的病毒載體和質粒DNA的開發和生產。 這些公司專注於戰略舉措，以提高市場佔有率並獲得競爭優勢。 Lonza Group 是市場領導者之一，它是一家全球合同開發和製造組織 (CDMO)。 Lonza 提供廣泛的服務，包括病毒載體製造、質粒 DNA 製造和工藝開發。 市場領導者和其他人採取的關鍵戰略包括投資研發活動以增強製造工藝、擴大產能以滿足不斷增長的需求以及利用新技術進入和進入市場，其中包括建立戰略合作夥伴關係和聯盟以擴大規模。 這些公司還專注於確保監管合規、質量保證和遵守良好生產規範，以滿足基因治療和疫苗行業的嚴格要求。 此外，新興公司和初創企業憑藉創新技術和平台進入市場，進一步加劇了病毒載體和質粒DNA製造市場的競爭。 這些公司正在利用生物技術和基因工程的進步來開發新型病毒載體和質粒 DNA 製造方法。

內容

第 1 章前言

  • 報告內容
    • 報告的目的
    • 目標受眾
    • 主要產品
  • 市場細分
  • 調查方法

第 2 章執行摘要

第 3 章病毒載體和質粒 DNA 製造市場：競爭分析

  • 主要供應商的市場定位
  • 供應商採取的策略
  • 主要產業戰略
  • 層級分析：2022 年與 2031 年

第 4 章病毒載體和質粒 DNA 製造市場：宏觀分析和市場動態

  • 簡介
  • 2021-2031 年全球病毒載體和質粒 DNA 製造市場價值
  • 市場動態
    • 市場促進因素
    • 市場抑制因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析

第 5 章病毒載體和質粒 DNA 製造市場：按載體類型 2021-2031

  • 市場概況
  • 增長和盈利分析：2022 年與 2031 年
  • 市場細分
    • 腺病毒
    • 逆轉錄病毒
    • 腺相關病毒（AAV）
    • 慢病毒
    • 質粒
    • 其他

第 6 章病毒載體和質粒 DNA 製造市場：按工作流程 2021-2031

  • 市場概況
  • 增長和盈利分析：2022 年與 2031 年
  • 市場細分
    • 上游製造流程
      • 向量放大/擴展
      • 載體恢復/收集
    • 下游製造流程
      • 細化
      • 填充和整理

第 7 章病毒載體和質粒 DNA 製造市場：按應用分類 2021-2031

  • 市場概況
  • 增長和盈利分析：2022 年與 2031 年
  • 市場細分
    • 反義/RNAi療法
    • 基因治療
    • 細胞療法
    • 疫苗開發
    • 研究用途

第 8 章病毒載體和質粒 DNA 製造市場：按最終用途 2021-2031

  • 市場概況
  • 增長和盈利分析：2022 年與 2031 年
  • 市場細分
    • 製藥和生物製藥公司
    • 研究院

第 9 章 2021-2031 年按疾病劃分的病毒載體和質粒 DNA 製造市場

  • 市場概況
  • 增長和盈利分析：2022 年與 2031 年
  • 市場細分
    • 癌症
    • 遺傳性疾病
    • 感染
    • 其他

第 10 章 2021-2031 年北美病毒載體和質粒 DNA 製造市場

  • 市場概況
  • 病毒載體和質粒 DNA 製造市場：按載體類型 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按工作流程 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按應用 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按最終用途 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按疾病分類 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按地區 2021-2031
    • 北美
      • 美國
      • 加拿大
      • 北美其他地區

第 11 章英國和歐盟病毒載體和質粒 DNA 製造市場 2021-2031

  • 市場概況
  • 病毒載體和質粒 DNA 製造市場：按載體類型 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按工作流程 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按應用 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按最終用途 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按疾病分類 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按地區 2021-2031
    • 英國/歐盟
      • 英國
      • 德國
      • 西班牙
      • 意大利
      • 法國
      • 其他歐洲地區

第 12 章亞太地區病毒載體和質粒 DNA 製造市場 2021-2031

  • 市場概況
  • 病毒載體和質粒 DNA 製造市場：按載體類型 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按工作流程 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按應用 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按最終用途 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按疾病分類 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按地區 2021-2031
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 亞太地區其他地區

第 13 章 2021-2031 年拉丁美洲病毒載體和質粒 DNA 製造市場

  • 市場概況
  • 病毒載體和質粒 DNA 製造市場：按載體類型 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按工作流程 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按應用 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按最終用途 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按疾病分類 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按地區 2021-2031
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地區

第 14 章中東和非洲病毒載體和質粒 DNA 製造市場 2021-2031

  • 市場概況
  • 病毒載體和質粒 DNA 製造市場：按載體類型 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按工作流程 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按應用 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按最終用途 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按疾病分類 2021-2031
  • 病毒載體和質粒 DNA 製造市場：按地區 2021-2031
    • 中東和非洲
      • 海灣合作委員會
      • 非洲
      • 其他中東和非洲地區

第 15 章公司簡介

  • Lonza
  • Catapult
  • uniQure N.V.
  • FUJIFILM Diosynth Biotechnologies
  • Kaneka Eurogentec S.A.
  • Oxford Biomedica
  • Spark Therapeutics Inc.
  • Cobrabiologics
  • Merck KGaA
  • 其他特色公司
Product Code: 139601-06-23

The viral vectors and plasmid DNA manufacturing market is expected to grow at a CAGR of 22.5% during the forecast period of 2023 to 2031, driven by the increasing demand for advanced gene therapies, vaccines, and cell-based therapies. The market revenue is expected to witness substantial growth in the coming years, with a promising compound annual growth rate (CAGR).Viral vectors and plasmid DNA are essential components in the development and production of gene therapies and vaccines. Viral vectors, such as adenoviruses, lentiviruses, and adeno-associated viruses (AAVs), are used to deliver genetic material into target cells, enabling the modification or correction of specific genes associated with various diseases. Plasmid DNA, on the other hand, serves as a vehicle for carrying therapeutic genes, providing the necessary instructions for protein synthesis within cells.The market for viral vectors and plasmid DNA manufacturing is driven by advancements in biotechnology and genetic engineering, which have revolutionized the field of medicine. Gene therapies have shown tremendous potential in treating a range of genetic disorders, rare diseases, and certain types of cancer. Additionally, the development of vaccines targeting infectious diseases and immunotherapies for cancer has further propelled the demand for viral vectors and plasmid DNA manufacturing.The COVID-19 pandemic has further accelerated the growth of this market, with a surge in research and development activities to develop vaccines and treatments. Several pharmaceutical companies and research organizations have focused their efforts on leveraging viral vectors and plasmid DNA to develop COVID-19 vaccines and therapeutics. This unprecedented global health crisis has highlighted the importance of viral vectors and plasmid DNA manufacturing capabilities in addressing emerging infectious diseases and public health challenges.

Growing Demand for Gene Therapies

The viral vectors and plasmid DNA manufacturing market is driven by the growing demand for gene therapies. Gene therapy offers a promising approach to treat a wide range of genetic disorders and inherited diseases by introducing functional genes into patients' cells. The increasing prevalence of genetic diseases, such as muscular dystrophy, cystic fibrosis, and hemophilia, has fuelled the demand for gene therapies. According to a study published in the Journal of the American Medical Association (JAMA), gene therapy has shown significant therapeutic benefits in clinical trials for various genetic disorders. The success of gene therapies in treating diseases that were previously untreatable or had limited treatment options has generated a strong market demand for viral vectors and plasmid DNA used in their manufacturing.

Advancements in Viral Vector Technology

Advancements in viral vector technology play a crucial role in driving the growth of the viral vectors and plasmid DNA manufacturing market. Researchers and biopharmaceutical companies are constantly working on improving the efficiency, safety, and specificity of viral vectors used in gene therapies and vaccines. For example, the development of new generation adeno-associated viruses (AAVs) with enhanced transduction capabilities and reduced immunogenicity has contributed to the success of several gene therapy trials. A study published in the journal Molecular Therapy demonstrated the potential of novel AAV variants in achieving efficient gene delivery. These advancements in viral vector technology have not only improved the efficacy of gene therapies but also expanded their application in various therapeutic areas, further driving the demand for viral vectors and plasmid DNA manufacturing.

Increasing Investments in Biotechnology Research and Development

The viral vectors and plasmid DNA manufacturing market is propelled by increasing investments in biotechnology research and development. Governments, pharmaceutical companies, and research institutions are allocating significant funds for the development of innovative therapies, including gene therapies and vaccines. For instance, the National Institutes of Health (NIH) in the United States has invested substantial resources in supporting gene therapy research and clinical trials. The European Union has also committed significant funding through its Horizon 2020 program for advancing biotechnology and gene therapy initiatives. These investments in research and development activities fuel the discovery of novel viral vectors and plasmid DNA manufacturing technologies, leading to the commercialization of advanced therapies. The growing financial support and focus on biotechnology research and development are expected to drive the viral vectors and plasmid DNA manufacturing market in the coming years.

Regulatory Challenges and Safety Concerns

The viral vectors and plasmid DNA manufacturing market faces regulatory challenges and safety concerns that serve as a restraint to its growth. The development and commercialization of gene therapies and vaccines involve stringent regulatory processes and safety assessments to ensure the efficacy and safety of these products. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose strict guidelines and requirements for the manufacturing, quality control, and clinical testing of viral vectors and plasmid DNA. Compliance with these regulations can be time-consuming and expensive for manufacturers, leading to delays in product approvals and market entry. Additionally, concerns about the potential risks associated with gene therapies, such as immune responses, off-target effects, and long-term safety profiles, pose challenges to the widespread adoption of these therapies. Reports of adverse events and safety issues in clinical trials can impact the perception and acceptance of gene therapies, affecting the demand for viral vectors and plasmid DNA manufacturing. For example, the safety concerns surrounding a gene therapy trial for the treatment of X-linked severe combined immunodeficiency (X-SCID) led to a temporary halt in the trial. These regulatory challenges and safety concerns pose a restraint to the viral vectors and plasmid DNA manufacturing market, necessitating rigorous compliance with regulations and continued research to ensure the safety and efficacy of gene therapies and vaccines.

Adenovirus Vectors Dominates the Market by Vector Type

The viral vectors and plasmid DNA manufacturing market can be segmented based on vector types, including adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Among these, AAV is expected to witness the highest CAGR during the forecast period of 2023 to 2031. AAV vectors have gained significant attention in gene therapy applications due to their ability to efficiently deliver therapeutic genes to target cells with low immunogenicity and long-term gene expression. The use of AAV vectors in approved gene therapies, such as Luxturna and Zolgensma, has showcased their potential in treating inherited genetic disorders. As a result, the demand for AAV vectors is increasing, driving the growth of the market in terms of CAGR. In terms of revenue, adenovirus vectors held the highest share in 2022 in the viral vectors and plasmid DNA manufacturing market. Adenovirus vectors are widely used in gene therapy research and clinical trials due to their high transduction efficiency and ability to accommodate large DNA inserts. They have demonstrated success in several gene therapy applications, particularly in cancer immunotherapies and vaccine development. Moreover, the robust manufacturing processes and well-established protocols for adenovirus vectors contribute to their dominant revenue position in the market. Retrovirus vectors, including lentivirus, also hold a significant revenue share, primarily driven by their use in CAR-T cell therapies and gene-modified cell therapies. Plasmids, which serve as essential tools in gene cloning and recombinant DNA technology, contribute to the market's revenue but have a comparatively lower growth rate. Other vector types, such as herpes simplex virus (HSV) vectors and vaccinia virus vectors, hold a smaller revenue share in the market. In summary, while adenovirus vectors generate the highest revenue, AAV vectors are expected to witness the highest CAGR, driven by their promising applications in gene therapies.

North America Leads the Revenues While APAC Leads the Growth

North America held a significant share in terms of revenue in the viral vectors and plasmid DNA manufacturing market in 2022. The region has a well-established biopharmaceutical industry, robust research infrastructure, and favorable regulatory frameworks that facilitate the development and commercialization of gene therapies and vaccines. Moreover, increasing investments in research and development activities, particularly in the United States, contribute to the market's revenue growth. Europe is also a prominent region in the viral vectors and plasmid DNA manufacturing market, with a significant revenue contribution. The presence of leading biopharmaceutical companies, advancements in biotechnology research, and strong government support drive the market's growth in this region. In terms of the highest CAGR during the forecast period of 2023 to 2031, Asia Pacific is expected to top the ranl. The region has witnessed rapid growth in the biotechnology sector, driven by factors such as increasing investments in research and development, rising healthcare expenditure, and a growing focus on personalized medicine. Countries like China, Japan, and India are emerging as key players in the viral vectors and plasmid DNA manufacturing market, leveraging their scientific expertise and expanding biopharmaceutical capabilities. Latin America and the Middle East and Africa regions are also witnessing steady growth in the market, driven by the increasing focus on improving healthcare infrastructure and the adoption of advanced medical technologies.

Market Competition to Intensify During the Forecast Period

The viral vectors and plasmid DNA manufacturing market is highly competitive, with several key players actively participating in the development and production of viral vectors and plasmid DNA for gene therapies and vaccines. These companies are focusing on strategic initiatives to strengthen their market presence and gain a competitive edge.One of the top players in the market is Lonza Group, a global contract development and manufacturing organization (CDMO). Lonza offers a wide range of services, including viral vector manufacturing, plasmid DNA production, and process development.Key strategies adopted by top players and others in the market include investing in research and development activities to enhance manufacturing processes, expanding production capacity to meet the growing demand, and establishing strategic partnerships and collaborations to access novel technologies and broaden their market reach. These companies are also focusing on ensuring regulatory compliance, quality assurance, and adherence to good manufacturing practices to meet the stringent requirements of the gene therapy and vaccine industry. Moreover, competition in the viral vectors and plasmid DNA manufacturing market is further intensified by emerging players and start-ups that are entering the market with innovative technologies and platforms. These players are leveraging advancements in biotechnology and genetic engineering to develop novel viral vectors and plasmid DNA manufacturing approaches.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofViral Vectors and Plasmid DNA Manufacturing market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Viral Vectors and Plasmid DNA Manufacturing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Vector Type

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

Workflow

  • Upstream Manufacturing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
  • Downstream Manufacturing
  • Purification
  • Fill Finish

Application

  • Antisense & RNAi Therapy
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

End-use

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Disease

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Viral Vectors and Plasmid DNA Manufacturing market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Viral Vectors and Plasmid DNA Manufacturing market?
  • Which is the largest regional market for Viral Vectors and Plasmid DNA Manufacturing market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Viral Vectors and Plasmid DNA Manufacturing market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Viral Vectors and Plasmid DNA Manufacturing market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Viral Vectors and Plasmid DNA Manufacturing Market
  • 2.2. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 (US$ Million)
  • 2.3. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 (US$ Million)
  • 2.4. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 (US$ Million)
  • 2.5. Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 (US$ Million)
  • 2.6. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 (US$ Million)
  • 2.7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022 (US$ Million)
  • 2.8. Attractive Investment Proposition by Geography, 2022

3. Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Analysis

  • 3.1. Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Vendors
  • 3.2. Strategies Adopted by Viral Vectors and Plasmid DNA Manufacturing Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Viral Vectors and Plasmid DNA Manufacturing Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Viral Vectors and Plasmid DNA Manufacturing Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Adenovirus
    • 5.3.2. Retrovirus
    • 5.3.3. Adeno-Associated Virus (AAV)
    • 5.3.4. Lentivirus
    • 5.3.5. Plasmids
    • 5.3.6. Others

6. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Upstream Manufacturing
      • 6.3.1.1. Vector Amplification & Expansion
      • 6.3.1.2. Vector Recovery/Harvesting
    • 6.3.2. Downstream Manufacturing
      • 6.3.2.1. Purification
      • 6.3.2.2. Fill Finish

7. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Antisense & RNAi Therapy
    • 7.3.2. Gene Therapy
    • 7.3.3. Cell Therapy
    • 7.3.4. Vaccinology
    • 7.3.5. Research Applications

8. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 8.3. Market Segmentation
    • 8.3.1. Pharmaceutical and Biopharmaceutical Companies
    • 8.3.2. Research Institutes

9. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 9.3. Market Segmentation
    • 9.3.1. Cancer
    • 9.3.2. Genetic Disorders
    • 9.3.3. Infectious Diseases
    • 9.3.4. Others

10. North America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 10.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 10.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 10.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 10.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 10.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 10.7.1.North America
      • 10.7.1.1. U.S.
        • 10.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 10.7.1.2. Canada
        • 10.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 10.7.1.3. Rest of North America
        • 10.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 10.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 10.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 10.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

11. UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 11.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 11.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 11.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 11.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 11.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 11.7.1.UK and European Union
      • 11.7.1.1. UK
        • 11.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.2. Germany
        • 11.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.3. Spain
        • 11.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.4. Italy
        • 11.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.5. France
        • 11.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 11.7.1.6. Rest of Europe
        • 11.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 11.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 11.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 11.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

12. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 12.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 12.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 12.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 12.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 12.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 12.7.1.Asia Pacific
      • 12.7.1.1. China
        • 12.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.2. Japan
        • 12.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.3. India
        • 12.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.4. Australia
        • 12.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.5. South Korea
        • 12.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 12.7.1.6. Rest of Asia Pacific
        • 12.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 12.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 12.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 12.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 13.1. Market Overview
  • 13.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 13.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 13.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 13.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 13.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 13.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 13.7.1.Latin America
      • 13.7.1.1. Brazil
        • 13.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 13.7.1.2. Mexico
        • 13.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 13.7.1.3. Rest of Latin America
        • 13.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 13.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 13.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 13.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

14. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)

  • 14.1. Market Overview
  • 14.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
  • 14.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
  • 14.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 14.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
  • 14.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
  • 14.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 14.7.1.Middle East and Africa
      • 14.7.1.1. GCC
        • 14.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 14.7.1.2. Africa
        • 14.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
      • 14.7.1.3. Rest of Middle East and Africa
        • 14.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
        • 14.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
        • 14.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 14.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
        • 14.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)

15. Company Profile

  • 15.1. Lonza
    • 15.1.1. Company Overview
    • 15.1.2. Financial Performance
    • 15.1.3. Product Portfolio
    • 15.1.4. Strategic Initiatives
  • 15.2. Catapult
    • 15.2.1. Company Overview
    • 15.2.2. Financial Performance
    • 15.2.3. Product Portfolio
    • 15.2.4. Strategic Initiatives
  • 15.3. uniQure N.V.
    • 15.3.1. Company Overview
    • 15.3.2. Financial Performance
    • 15.3.3. Product Portfolio
    • 15.3.4. Strategic Initiatives
  • 15.4. FUJIFILM Diosynth Biotechnologies
    • 15.4.1. Company Overview
    • 15.4.2. Financial Performance
    • 15.4.3. Product Portfolio
    • 15.4.4. Strategic Initiatives
  • 15.5. Kaneka Eurogentec S.A.
    • 15.5.1. Company Overview
    • 15.5.2. Financial Performance
    • 15.5.3. Product Portfolio
    • 15.5.4. Strategic Initiatives
  • 15.6. Oxford Biomedica
    • 15.6.1. Company Overview
    • 15.6.2. Financial Performance
    • 15.6.3. Product Portfolio
    • 15.6.4. Strategic Initiatives
  • 15.7. Spark Therapeutics, Inc.
    • 15.7.1. Company Overview
    • 15.7.2. Financial Performance
    • 15.7.3. Product Portfolio
    • 15.7.4. Strategic Initiatives
  • 15.8. Cobrabiologics
    • 15.8.1. Company Overview
    • 15.8.2. Financial Performance
    • 15.8.3. Product Portfolio
    • 15.8.4. Strategic Initiatives
  • 15.9. Merck KGaA
    • 15.9.1. Company Overview
    • 15.9.2. Financial Performance
    • 15.9.3. Product Portfolio
    • 15.9.4. Strategic Initiatives
  • 15.10. Other Notable Players
    • 15.10.1. Company Overview
    • 15.10.2. Financial Performance
    • 15.10.3. Product Portfolio
    • 15.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 2 Global Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 3 Global Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 4 Global Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 5 Global Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 6 Global Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 7 Global Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 8 North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 9 North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 10 North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 11 North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 12 North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 13 North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 14 North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 15 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 16 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 17 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 18 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 20 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 21 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 22 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 23 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 24 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 25 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 26 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 27 Canada Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 28 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 29 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 30 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 31 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 32 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 33 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 34 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 35 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 36 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 37 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 38 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 39 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 40 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 41 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 42 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 43 UK Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 44 UK Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 45 UK Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 46 UK Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 47 UK Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 48 UK Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 49 UK Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 50 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 51 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 52 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 53 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 54 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 55 Germany Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 56 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 57 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 58 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 59 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 60 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 61 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 62 Spain Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 63 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 64 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 65 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 66 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 67 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 68 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 69 Italy Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 70 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 71 France Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 72 France Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 73 France Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 74 France Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 75 France Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 76 France Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 77 France Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 78 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 79 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 80 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 81 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 82 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 83 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 84 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 85 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 86 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 87 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 88 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 89 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 90 Asia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 91 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 92 China Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 93 China Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 94 China Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 95 China Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 96 China Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 97 China Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 98 China Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 99 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 100 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 101 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 102 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 103 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 104 Japan Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 105 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 106 India Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 107 India Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 108 India Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 109 India Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 110 India Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 111 India Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 112 India Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 113 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 114 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 115 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 116 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 117 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 118 Australia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 119 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 120 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 121 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 122 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 123 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 124 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 125 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 126 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 127 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 128 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 129 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 130 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 131 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 132 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 133 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 134 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 135 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 136 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 137 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 138 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 139 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 140 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 141 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 142 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 143 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 144 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 145 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 146 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 147 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 148 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 149 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 150 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 151 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 152 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 153 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 154 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 155 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 156 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 157 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 158 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 159 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 160 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 161 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 162 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 163 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 164 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 165 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 166 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 167 GCC Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 168 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 169 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 170 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 171 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 172 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 173 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 174 Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 175 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
  • TABLE 176 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
  • TABLE 177 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
  • TABLE 178 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)

TABLE 179 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)

TABLE 180 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)

  • TABLE 181 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
  • TABLE 182 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Viral Vectors and Plasmid DNA Manufacturing Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Viral Vectors and Plasmid DNA Manufacturing Market: Quality Assurance
  • FIG. 5 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022
  • FIG. 6 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022
  • FIG. 7 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022
  • FIG. 8 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022
  • FIG. 9 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022
  • FIG. 10 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022
  • FIG. 11 Market Geographical Opportunity Matrix - Global Viral Vectors and Plasmid DNA Manufacturing Market, 2022

FIG. 12Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Players, 2022

FIG. 13Global Viral Vectors and Plasmid DNA Manufacturing Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 14 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 Vs 2031, %
  • FIG. 15 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 Vs 2031, %
  • FIG. 16 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 Vs 2031, %
  • FIG. 17 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 Vs 2031, %
  • FIG. 18 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 Vs 2031, %
  • FIG. 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 20 Canada Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 22 UK Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 23 Germany Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 24 Spain Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 25 Italy Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 26 France Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 28 China Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 29 Japan Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 30 India Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 31 Australia Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 32 South Korea Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Asia Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 34 Brazil Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 35 Mexico Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 36 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 37 GCC Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 38 Africa Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 39 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031